RESUMEN
BACKGROUND AND AIMS: In patients with noncirrhotic chronic extrahepatic portal vein obstruction (EHPVO), data on the morbimortality of abdominal surgery are scarce. APPROACH AND RESULTS: We retrospectively analyzed the charts of 76 patients (78 interventions) with EHPVO undergoing abdominal surgery within the Vascular Disease Interest Group network. Fourteen percent of the patients had ≥1 major bleeding (unrelated to portal hypertension) and 21% had ≥1 Dindo-Clavien grade ≥3 postoperative complications within 1 month after surgery. Fifteen percent had ≥1 portal hypertension-related complication within 3 months after surgery. Three patients died within 12 months after surgery. An unfavorable outcome (ie, ≥1 abovementioned complication or death) occurred in 37% of the patients and was associated with a history of ascites and with nonwall, noncholecystectomy surgical intervention: 17% of the patients with none of these features had an unfavorable outcome, versus 48% and 100% when one or both features were present, respectively. We then compared 63/76 patients with EHPVO with 126 matched (2:1) control patients without EHPVO but with similar surgical interventions. As compared with control patients, the incidence of major bleeding ( p <0.001) and portal hypertension-related complication ( p <0.001) was significantly higher in patients with EHPVO, but not that of grade ≥3 postoperative complications nor of death. The incidence of unfavorable postoperative outcomes was significantly higher in patients with EHPVO than in those without (33% vs. 18%, p =0.01). CONCLUSIONS: Patients with EHPVO are at high risk of major perioperative or postoperative bleeding and postoperative complications, especially in those with ascites or undergoing surgery other than wall surgery or cholecystectomy.
RESUMEN
Transplantation oncology represents a specificity of liver transplantation. Hepatocellular carcinoma is now an accepted indication with very good long-term results. Cholangiocarcinoma, hepatic -metastases from colorectal cancer and neuroendocrine tumors are emerging indications with outcome superior to those that can be achieved with systemic treatments in very selected patients.
La transplantation pour des indications oncologiques représente une particularité exclusive de la transplantation hépatique. Le carcinome hépatocellulaire est désormais une indication confirmée par de très bons résultats à long terme. Le cholangiocarcinome, les métastases hépatiques du cancer colorectal et neuroendocrine représentent des indications émergentes avec des résultats supérieurs à ceux obtenus avec les traitements systémiques, sous réserve d'une rigoureuse sélection des patients.
Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Trasplante de Hígado , Humanos , Trasplante de Hígado/métodos , Neoplasias Hepáticas/cirugía , Carcinoma Hepatocelular/cirugía , Colangiocarcinoma/cirugía , Neoplasias Colorrectales/cirugía , Tumores Neuroendocrinos/cirugíaRESUMEN
Liver transplantation is the best treatment option for patients with end-stage liver failure, as well as for various oncological (hepatic or extrahepatic), metabolic and genetic indications. Cirrhosis and its complications represent the most frequent indication for transplantation. This treatment option should be considered for cirrhotic patients with significant liver failure, the development of hepatocellular carcinoma or when complications linked to portal hypertension appear. In view of the limited availability of organs and a waiting time on the list estimated at around one year in Switzerland, careful assessment of the risk-benefit ratio and correct timing of evaluation in a transplant center are crucial to optimize the benefits of this procedure.
La transplantation du foie est la meilleure option thérapeutique pour les patients atteints d'une insuffisance hépatique terminale ainsi que pour différentes indications oncologiques (hépatiques ou extrahépatiques), métaboliques et génétiques. La cirrhose et ses complications représentent l'indication la plus fréquente à la transplantation. Celle-ci doit être évoquée chez un patient cirrhotique en cas d'insuffisance hépatique marquée, d'apparition d'un carcinome hépatocellulaire ou lors de complications liées à l'hypertension portale. Vu la disponibilité limitée des organes et d'un temps d'attente en liste de transplantation pouvant être supérieur à un an en Suisse, l'évaluation du rapport bénéfices-risques de la transplantation ainsi que du meilleur moment pour un bilan pré-greffe permet d'optimiser les bénéfices de cette intervention.
Asunto(s)
Carcinoma Hepatocelular , Fallo Hepático , Neoplasias Hepáticas , Trasplante de Hígado , Humanos , Adulto , Cirrosis Hepática/complicaciones , Cirrosis Hepática/cirugía , Carcinoma Hepatocelular/cirugía , Neoplasias Hepáticas/cirugíaRESUMEN
A close collaboration between the general practitioner and the gastroenterologist is necessary to optimize the management of a patient with cirrhosis, a frequent and serious complication of chronic liver diseases. Both the treatment of the etiological factor of liver disease and the surveillance of potential complications of cirrhosis are key issues in the proper management of cirrhosis. Preventive measures aim at keeping the patient in a compensated form of cirrhosis which is associated with a better survival. We address here the updated management strategies regarding the most frequent complications of cirrhosis.
La prise en charge d'un patient atteint de cirrhose implique une collaboration étroite entre le médecin généraliste et le spécialiste, combine le traitement de la maladie causale ainsi que la mise en place d'une surveillance des complications pouvant occasionner une décompensation avec un impact pronostique négatif. Nous passons en revue les principales situations cliniques de la cirrhose pour lesquelles des recommandations actualisées ont pour but d'améliorer la prise en charge de cette maladie fréquente grevée d'une importante morbimortalité.
Asunto(s)
Cuidados Posteriores , Cirrosis Hepática , Cuidados Posteriores/normas , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Gastroenterólogos , Humanos , Médicos GeneralesRESUMEN
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARSCoV2) has a tropism for the gastrointestinal tract and several studies have shown an alteration of the gut microbiota in hospitalized infected patients. However, long-term data on microbiota changes after recovery are lacking. METHODS: We enrolled 30 patients hospitalized for SARSCoV2-related pneumonia. Their gut microbiota was analyzed within 48 h from the admission and compared with (1) that of other patients admitted for suspected bacterial pneumonia (control group) (2) that obtained from the same subject 6 months after nasopharyngeal swab negativization. RESULTS: Gut microbiota alpha-diversity increased 6 months after the resolution of SARS-CoV-2 infection. Bacteroidetes relative abundance was higher (≈ 36.8%) in patients with SARS-CoV-2, and declined to 18.7% when SARS-CoV-2 infection resolved (p = 0.004). Conversely, Firmicutes were prevalent (≈ 75%) in controls and in samples collected after SARS-CoV-2 infection resolution (p = 0.001). Ruminococcaceae, Lachnospiraceae and Blautia increased after SARS-CoV-2 infection resolution, rebalancing the gut microbiota composition. CONCLUSION: SARS-CoV-2 infection is associated with changes in the gut microbiome, which tend to be reversed in long-term period.